ScreenerHero

VALNValneva SE

NAS · US · Healthcare · Biotechnology · valneva.com
6.960USDMkt Cap: 659.97M $P/E: —

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese ence…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap659.97M $
Enterprise Value735.40M $
Revenue (TTM)142.94M $
Gross Profit67.52M $
Net Income (TTM)-115.19M $
Revenue/Share1.602 USD
Last Price6.960 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees620
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINCH0002088976
Valuation
P/E (Trailing)—
P/E (Forward)5.73
PEG—
EV/EBITDA-7.45
EV/Revenue5.14
P/S4.52
P/B6.89
EPS (TTM)-2.07
EPS (Forward)1.19
52W Range
6.71371% of range7.059
52W High7.059 USD
52W Low6.713 USD
Profitability
Gross Margin38.66%
Oper. Margin-74.92%
EBITDA Margin-69.07%
Profit Margin-65.95%
ROE-108.50%
ROA-28.88%
Growth
Revenue Growth-27.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-52.89M $
CapEx (TTM)4.48M $
FCF Margin-29.73%
FCF Yield-6.44%
Net Debt88.71M $
Net Debt/EBITDA-0.90
Balance Sheet
Debt/Equity1.95
Current Ratio2.16
Quick Ratio1.33
Book Value/Sh0.9895 USD
Cash/Share1.282 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.0 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)12.25 USD
Upside (mean)+76.0%
Target Range5.000 USD – 18.00 USD
$5.000+76.0% to mean$18.00
# Analysts4
Ownership
Shares Out.94.82M
Float78.63M
Insiders0.00%
Institutions3.99%
Short Interest
Short Ratio6.6d
Short % Float0.16%
Short % Out.0.16%
Shares Short158.67K
Short (prev mo.)182.10K
Technical
SMA 505.339 (+30.4%)
SMA 2007.519 (-7.4%)
Beta1.35
S&P 52W Chg21.00%
Avg Vol (30d)21.54K
Avg Vol (10d)349.65K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—